Werewolf Therapeutics (HOWL) EBITDA Margin (2022 - 2026)

Werewolf Therapeutics (HOWL) posted quarterly EBITDA Margin of 34.09% for Q2 2026, up 100.03% on a QoQ basis from 135653.33% in Q4 2024.

Werewolf Therapeutics (HOWL) EBITDA Margin (2022 - 2026) Analysis & Trends

Werewolf Therapeutics has reported EBITDA Margin for 4 years, with the latest figure at 34.09% in Q2 2026.

EBITDA Margin for Q2 2026 came in at 34.09%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was 148.84% (up 48655116.0% YoY), and the FY2024 annual result was 3873.37%, down 367027.0% from the prior year.
EBITDA Margin advanced to 34.09% in Q2 2026, from 135653.33% in the prior quarter.
Over five years, EBITDA Margin peaked at 34.09% in Q2 2026 and troughed at 135653.33% in Q4 2024.
A 4-year average of 12886.77% and a median of 273.81% in 2023 frame the typical range for EBITDA Margin.
The widest annual swing landed in 2023, when EBITDA Margin soared 28587 bps; it then sank 13478978 bps in 2024.
A 4-year view of EBITDA Margin shows it stood at 180.96% in 2022, then slumped by 377 bps to 863.56% in 2023, then plunged by 15609 bps to 135653.33% in 2024, then soared by 100 bps to 34.09% in 2026.
Per Business Quant data, the three most recent EBITDA Margin figures were 34.09% in Q2 2026, 135653.33% in Q4 2024, and 1658.79% in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	Werewolf Therapeutics	20.90 Mn	20.90 Mn	-	34.09%

Download Data